Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases

Trends in Endocrinology and Metabolism

Volumn 12, Issue 9, 2001, Pages 384-390

  Mitsiades, Nicholas ^a   Poulaki, Vassiliki ^a   Mitsiades, Constantine S ^b   Koutras, Demetrios A ^c   Chrousos, George P ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; FAS ANTIGEN; FAS LIGAND; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; GRAVES DISEASE; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; THYROID DISEASE; THYROID TUMOR;

ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; FAS LIGAND PROTEIN; GRAVES DISEASE; HUMANS; MEMBRANE GLYCOPROTEINS; THYROID DISEASES; THYROID NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035511818     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(01)00441-6     Document Type: Review

References (60)

1. Thompson, C.B. (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267, 1458-1462
2. Adams, J.M. and Cory, S. (1998) The Bcl-2protein family: arbiters of cell survival. Science 281, 1322-1326
3. Schulze-Osthoff, K. et al (1988) Apoptosis signaling by death receptors. Eur. J. Biochem. 254, 439-459
4. Muzio, M. et al. (1998) An induced proximity model for caspase-8 activation. J. Biol. Chem. 273, 2926-2930
5. Salvesen, G.S. and Dixit, V.M. (1999) Caspase activation: the induced-proximity model. Proc. Natl. Acad Sci. U. S. A. 96, 10964-10967
6. Poulaki, V. et al. (2001) Fas/Fas ligand-associated apoptosis in experimental autoimmune uveoretinitis in rodents: role of proinflammatory corticotropin-releasing hormone. Exp. Eye Res. 72, 623-629
7. Ashkenazi, A and Dixit, V.M. (1999) Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11, 255-260
8. Jo, M. et al. (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 6, 564-567
9. Lawrence, D. et al. (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7, 383-385
10. Walczak, H. et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 5, 157-163
11. Ashkenazi, A et al. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162
12. Griffith, T.S. et al. (1998) Intracellular regulation of TRATL-induced apoptosis in human melanoma cells. J. Immunol. 161, 2833-2840
13. Keane, M.M. et al. (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59, 734-741
14. O'Connell, J. et al (1999) The Fas counterattack: cancer as a site of immune privilege. Immunol. Today 20, 46-52
15. Hahne, M. et al. (1996) Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363-1366
16. Mitsiades, N. et al. (1998) Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved in to a soluble form by a metalloproteinase. Am. J. Pathol. 153, 1947-1956
17. Poulaki, V. et al. (2000) Fasl gene regulation by MycN in neuroblastoma (NB) cells. Proc. Am. Assoc. Cancer Res. 41, 416
18. Hedlund, T.E. et al. (1998) Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage. Prostate 36, 92-101
19. Owen-Schaub, L.B. et al. (1998) Fas and Fas ligand interactions suppress melanoma lung metastasis. J. Exp. Med. 188, 1717-1723
20. Mitsiades, N. et al. (2001) Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 61, 577-581
21. Muschen, M. et al. (2000) Defining CD95 as a tumor suppressor gene. J. Mol. Med. 78, 312-325
22. Irmler, M. et al. (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388, 190-195
23. Myc, A. et al. (1999) Characterization of FAP-1 expression and function in thyroid follicular cells. Endocrinology 140, 5431-5434
24. Giordano, C. et al. (1997) Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275, 960-963
25. Batteux, F. et al. (1999) Gene therapy of experimental autoimmune thyroiditis by in vivo administration of plasmid DNA coding for Fas ligand. J. Immunol. 162, 603-608
26. Mitsiades, N. et al. (1998) Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis. J. Clin. Endocrinol. Metab. 83, 2199-2203
27. Mitsiades, N. et al. (1999) Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. J. Clin. Endocrinol. Metab. 84, 2924-2932
28. Hiromatsu, Y. et al (1999) Functional Fas ligand expression in thyrocytes from patients with Graves' disease. J. Clin Endocrinol. Metab. 84, 2896-2902
29. Leithauser, F et al. (1993) Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest 69, 415-429
30. Tanimoto, C. et al. (1995) Apoptosis in thyroid diseases: a histochemical study. Endocr. J. 42, 193-201
31. Kawakami, A. et al. (1996) Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro. Endocrinology 137, 3163-3169
32. Arscott, P.L. et al. (1997) Fas (APO-1, CD95)-mediated apoptosis in thyroid cells is regulated by a labile protein inhibitor. Endocrinology 138, 5019-5027
33. Mitsiades, N. et al. (2000) Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 60, 4122-4129
34. Baker, J.R, Jr (1999) Dying (apoptosing?) for a consensus on the Fas death pathway in the thyroid. J. Clin. Endocrinol. Metab. 84, 2593-2595
35. Baker, J.R, Jr and Bretz, J.D. (2000) Specificity questions concerning the clone 33 anti-fas ligand antibody. Cell Death Differ. 7, 8-9
36. Batteux, F et al. (2000) Transgenic expression of Fas ligand on thyroid follicular cells prevents autoimmune thyroiditis. J. Immunol. 164, 1681-1688
37. Hammond, L.J. et al. (1997) Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis. J. Pathol. 182, 138-144
38. Arscott, P.L. and Baker, J.R, Jr (1998) Apoptosis and thyroiditis. Clin. Immunol. Immunopathol. 87, 207-217
39. Borgerson, K.L. et al. (1999) The role of Fas-mediated apoptosis in thyroid autoimmune disease. Autoimmunity 30, 251-264
40. Kotani, T. et al. (1995) Apoptosis in thyroid tissue from patients with Hashimoto's thyroiditis. Autoimmunity 20, 231-236
41. Weetman, A.P. and McGregor, A.M. (1994) Autoimmune thyroid disease: further developments in our understanding. Endocr. Rev. 15, 788-830
42. Bretz, J.D. et al. (1999) Inflammatory cytokine regulation of Fas-mediated apoptosis in thyroid follicular cells. J. Biol. Chem. 274, 25433-25438
43. Stassi, G. et al (2000) Control of target cell survival in thyroid auto immunity by T helper cytokines via regulation of apoptotic proteins. Nat. Immunol. 1, 483-488
44. Bretz, J.D. et al. (1999) TRAIL death pathway expression and induction in thyroid follicular cells. J. Biol. Chem. 274, 23627-23632
45. Mitsiades, N. et al. (2000) Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves' disease. Thyroid 10, 527-532
46. McGregor, A.M. et al. (1980) Carbimazole and the autoimmune response in Graves' disease. New Engl. J. Med. 303, 302-307
47. Young, R. J. et al. (1976) Histometry of lymphoid infiltrate in the thyroid of primary thyrotoxicosis patients. Relation of extent of thyroiditis to preoperative drug treatment and postoperative hypothyroidism. J. Clin. Pathol. 29, 398-402
48. Beck, J.S. et al. (1973) Lymphoid tissue in the thyroidgland and thymus of patients with primary thyrotoxicosis. Br. J. Surg. 60, 769-771
49. Volpe, R. (1994) Evidence that the immunosuppressive effects of an tithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signaling: a review. Thyroid 4, 217-223
50. Strand, S. et al. (1996) Lymphocyte apoptosis inducedby CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat. Med. 2, 1361-1366
51. Arscott, P.L. et al. (1999) Fas (CD95) expression is up-regulated on papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 84, 4246-4252
52. Basolo, F. et al. (1997) Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p 53 protein expression. Br. J. Cancer 75, 537-541
53. Baker, J.R., Jr (1995) The immune response to papillary thyroid cancer. J. Clin Endocrinol. Metab. 80, 3419-3420
54. Ogasawara, J. et al. (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364, 806-809
55. Ahmad, M. and Shi, Y. (2000) TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention. Oncogene 19, 3363-3371
56. Mitsiades, N. et al. (2001) Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and express DR4 and DR5 receptors. Cancer Res. 61, 2704-2712
57. Sprick, M.R. et al. (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12, 599-609
58. Kischkel, F.C. et al. (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611-620
59. Thome, M. et al. (1997) Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386, 517-521
60. Jin, Z. and El-Deiry, W.S. (2001) Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Proc. Am. Assoc. Cancer Res. 42, 438